187 related articles for article (PubMed ID: 7547235)
1. MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status.
Foulkes WD; Stamp GW; Afzal S; Lalani N; McFarlane CP; Trowsdale J; Campbell IG
Br J Cancer; 1995 Oct; 72(4):883-8. PubMed ID: 7547235
[TBL] [Abstract][Full Text] [Related]
2. MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status.
Flørenes VA; Maelandsmo GM; Forus A; Andreassen A; Myklebost O; Fodstad O
J Natl Cancer Inst; 1994 Sep; 86(17):1297-302. PubMed ID: 8064888
[TBL] [Abstract][Full Text] [Related]
3. Altered patterns of MDM2 and TP53 expression in human bladder cancer.
Lianes P; Orlow I; Zhang ZF; Oliva MR; Sarkis AS; Reuter VE; Cordon-Cardo C
J Natl Cancer Inst; 1994 Sep; 86(17):1325-30. PubMed ID: 8064890
[TBL] [Abstract][Full Text] [Related]
4. TP53 protein accumulation and gene mutation in relation to overexpression of MDM2 protein in ovarian borderline tumours and stage I carcinomas.
Skomedal H; Kristensen GB; Abeler VM; Børresen-Dale AL; Tropé C; Holm R
J Pathol; 1997 Feb; 181(2):158-65. PubMed ID: 9120719
[TBL] [Abstract][Full Text] [Related]
5. Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry.
Nenutil R; Smardova J; Pavlova S; Hanzelkova Z; Muller P; Fabian P; Hrstka R; Janotova P; Radina M; Lane DP; Coates PJ; Vojtesek B
J Pathol; 2005 Nov; 207(3):251-9. PubMed ID: 16161005
[TBL] [Abstract][Full Text] [Related]
6. Amplification of Mdmx and overexpression of MDM2 contribute to mammary carcinogenesis by substituting for p53 mutations.
Yu Q; Li Y; Mu K; Li Z; Meng Q; Wu X; Wang Y; Li L
Diagn Pathol; 2014 Mar; 9():71. PubMed ID: 24667108
[TBL] [Abstract][Full Text] [Related]
7. DNA amplifications at 20q13 and MDM2 define distinct subsets of evolved breast and ovarian tumours.
Courjal F; Cuny M; Rodriguez C; Louason G; Speiser P; Katsaros D; Tanner MM; Zeillinger R; Theillet C
Br J Cancer; 1996 Dec; 74(12):1984-9. PubMed ID: 8980401
[TBL] [Abstract][Full Text] [Related]
8. Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein status.
McCann AH; Kirley A; Carney DN; Corbally N; Magee HM; Keating G; Dervan PA
Br J Cancer; 1995 May; 71(5):981-5. PubMed ID: 7734324
[TBL] [Abstract][Full Text] [Related]
9. P53 and MDM2 co-expression in tobacco and betel chewing-associated oral squamous cell carcinomas.
Shwe M; Chiguchi G; Yamada S; Nakajima T; Maung KK; Takagi M; Amagasa T; Tsuchida N
J Med Dent Sci; 2001 Dec; 48(4):113-9. PubMed ID: 12160248
[TBL] [Abstract][Full Text] [Related]
10. [Interaction between p53 and MDM2 in human lung cancer cells].
Rybárová S; Hodorová I; Vecanová J; Muri J; Mihalik J
Klin Onkol; 2014; 27(1):33-7. PubMed ID: 24635435
[TBL] [Abstract][Full Text] [Related]
11. Analysis of p53 and mdm2 proteins in malignant fibrous histiocytoma in absence of gene alteration: prognostic significance.
Molina P; Pellín A; Navarro S; Boix J; Carda C; Llombart-Bosch A
Virchows Arch; 1999 Dec; 435(6):596-605. PubMed ID: 10628802
[TBL] [Abstract][Full Text] [Related]
12. MDM2 gene amplification and expression in non-small-cell lung cancer: immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulation.
Higashiyama M; Doi O; Kodama K; Yokouchi H; Kasugai T; Ishiguro S; Takami K; Nakayama T; Nishisho I
Br J Cancer; 1997; 75(9):1302-8. PubMed ID: 9155050
[TBL] [Abstract][Full Text] [Related]
13. Distinct mdm2/p53 expression patterns in liposarcoma subgroups: implications for different pathogenetic mechanisms.
Pilotti S; Della Torre G; Lavarino C; Di Palma S; Sozzi G; Minoletti F; Rao S; Pasquini G; Azzarelli A; Rilke F; Pierotti MA
J Pathol; 1997 Jan; 181(1):14-24. PubMed ID: 9071998
[TBL] [Abstract][Full Text] [Related]
14. Oncogene amplification in urothelial cancers with p53 gene mutation or MDM2 amplification.
Habuchi T; Kinoshita H; Yamada H; Kakehi Y; Ogawa O; Wu WJ; Takahashi R; Sugiyama T; Yoshida O
J Natl Cancer Inst; 1994 Sep; 86(17):1331-5. PubMed ID: 8064891
[TBL] [Abstract][Full Text] [Related]
15. Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification.
Riemenschneider MJ; Büschges R; Wolter M; Reifenberger J; Boström J; Kraus JA; Schlegel U; Reifenberger G
Cancer Res; 1999 Dec; 59(24):6091-6. PubMed ID: 10626796
[TBL] [Abstract][Full Text] [Related]
16. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations.
Reifenberger G; Liu L; Ichimura K; Schmidt EE; Collins VP
Cancer Res; 1993 Jun; 53(12):2736-9. PubMed ID: 8504413
[TBL] [Abstract][Full Text] [Related]
17. Rare MDM4 gene amplification in colorectal cancer: The principle of a mutually exclusive relationship between MDM alteration and TP53 inactivation is not applicable.
Suda T; Yoshihara M; Nakamura Y; Sekiguchi H; Godai TI; Sugano N; Tsuchida K; Shiozawa M; Sakuma Y; Tsuchiya E; Kameda Y; Akaike M; Matsukuma S; Miyagi Y
Oncol Rep; 2011 Jul; 26(1):49-54. PubMed ID: 21503588
[TBL] [Abstract][Full Text] [Related]
18. p53 mutation, murine double minute 2 amplification, and human papillomavirus infection are frequently involved but not associated with each other in esophageal squamous cell carcinoma.
Shibagaki I; Tanaka H; Shimada Y; Wagata T; Ikenaga M; Imamura M; Ishizaki K
Clin Cancer Res; 1995 Jul; 1(7):769-73. PubMed ID: 9816044
[TBL] [Abstract][Full Text] [Related]
19. P53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines.
Taylor AC; Shu L; Danks MK; Poquette CA; Shetty S; Thayer MJ; Houghton PJ; Harris LC
Med Pediatr Oncol; 2000 Aug; 35(2):96-103. PubMed ID: 10918230
[TBL] [Abstract][Full Text] [Related]
20. MDM2 overexpression is associated with short survival in adults with medulloblastoma.
Giordana MT; Duó D; Gasverde S; Trevisan E; Boghi A; Morra I; Pradotto L; Mauro A; Chió A
Neuro Oncol; 2002 Apr; 4(2):115-22. PubMed ID: 11916503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
